Premium
This is an archive article published on April 9, 2020

Foreign Secy Shringla calls up US, talks pandemic control

The phone conversation between Shringla, who was earlier India's envoy to the US, and Biegun took place a day after India said it will supply essential drugs to “some nations who have been particularly badly affected” by COVID-19.

coronavirus, india US Hydroxychloroquine, trump Hydroxychloroquine india, trump modi Hydroxychloroquine, trump thanks modi Hydroxychloroquine, india coronavirus, US coronavirus Earlier, Prime Minister Narendra Modi and US President Donald Trump had a telephonic conversation over the issue of Hydroxychloroquine supply to the US. (File)

Foreign Secretary Harsh Vardhan Shringla spoke to US Deputy Secretary of State Stephen E Biegun on Wednesday and discussed how to control the pandemic, including through development of “novel therapies” and prophylactics against COVID-19 and “ensure availability of essential medicines, diagnostic and medical equipment, and sharing of best practices and information”.

The phone conversation between Shringla, who was earlier India’s envoy to the US, and Biegun took place a day after India said it will supply essential drugs to “some nations who have been particularly badly affected” by COVID-19, and to “neighbouring countries who are dependent on India’s capabilities”.

New Delhi announced the decision shortly after US President Donald Trump said that “there may be retaliation” if India does not agree to export Hydroxychloroquine (HCQ), a key anti-malaria drug.

Story continues below this ad

Sources said Shringla and Biegun “discussed ways to further enhance their cooperation to counter and control the COVID-19 pandemic”. They exchanged views on the COVID-19 situation and associated challenges, a source said.

Earlier, Prime Minister Narendra Modi and US President Donald Trump had a telephonic conversation over the issue. External Affairs Minister S Jaishankar and US Secretary of State Pompeo had also spoken over phone to discuss the issue.

On Wednesday, US President Donald Trump tweeted, “Extraordinary times require even closer cooperation between friends. Thank you India and the Indian people for the decision on HCQ. Will not be forgotten! Thank you Prime Minister @NarendraModi for your strong leadership in helping not just India, but humanity, in this fight!”

On HCQ, New Delhi had said on Tuesday that a “comprehensive assessment” of India’s domestic requirements was carried out and it has confirmed the “availability of medicines for all possible contingencies”. It also said that the stock position “could allow” Indian companies to meet their export commitments already made.

Story continues below this ad

Also Read | Trump snaps at WHO — and India quietly sidestepped some of its advisories on virus

On April 4, after US President Donald Trump had made the request for supplies of HCQ in a phone call to PM Modi, New Delhi was “considering the request”, The Indian Express had reported.

Incidentally, that same day, the government had banned exports of HCQ, a drug Trump has repeatedly touted as a “game-changer” in the fight against COVID-19, but whose effectiveness is being debated. Besides the US, Brazil, some European countries and neighbouring countries are also asking for HCQ.

HCQ tablets are recognised as a prophylactic for those on the frontline of the fight against COVID-19 — doctors, nurses, paramedics and first responders — and can be used to treat patients infected with the virus.

Story continues below this ad

With more than 350,000 confirmed cases of coronavirus infection and over 10,000 deaths, the US has emerged as the new epicentre of the pandemic. In India too, the cases crossed 5,000 and 149 deaths were reported by the Health ministry on its website on Wednesday, 9.30 pm IST.

Here’s a quick Coronavirus guide from Express Explained to keep you updated: What can cause a COVID-19 patient to relapse after recovery? | COVID-19 lockdown has cleaned up the air, but this may not be good news. Here’s why | Can alternative medicine work against the coronavirus? | A five-minute test for COVID-19 has been readied, India may get it too | How India is building up defence during lockdown | Why only a fraction of those with coronavirus suffer acutely | How do healthcare workers protect themselves from getting infected? | What does it take to set up isolation wards?

Shubhajit Roy, Diplomatic Editor at The Indian Express, has been a journalist for more than 25 years now. Roy joined The Indian Express in October 2003 and has been reporting on foreign affairs for more than 17 years now. Based in Delhi, he has also led the National government and political bureau at The Indian Express in Delhi — a team of reporters who cover the national government and politics for the newspaper. He has got the Ramnath Goenka Journalism award for Excellence in Journalism ‘2016. He got this award for his coverage of the Holey Bakery attack in Dhaka and its aftermath. He also got the IIMCAA Award for the Journalist of the Year, 2022, (Jury’s special mention) for his coverage of the fall of Kabul in August 2021 — he was one of the few Indian journalists in Kabul and the only mainstream newspaper to have covered the Taliban’s capture of power in mid-August, 2021. ... Read More

Stay updated with the latest - Click here to follow us on Instagram

Latest Comment
Post Comment
Read Comments
Advertisement

You May Like

Advertisement